Author is bullish on SLS after slow phase 3 event accumulation suggests GPS is extending overall survival and may lead to efficacy halt or buyout.
SLS — LONG Author believes SELLAS Life Sciences' GPS phase 3 trial is tracking positively because only 12 events occurred in the past year versus 60 the prior year, implying the drug is extending overall survival. He estimates the win-to-fail ratio has improved and the trial could be halted for efficacy. He plans to hold through phase 3 results and a potential buyout, with SLS009 entering phase 3 this year as a follow-on asset.
The win to fail ratio has only improved and it could even be halted for efficacy.
This Reddit post, published January 02, 2026, features u/More_Advertising_383 discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/More_Advertising_383 · Tickers: SLS